Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995257 | 0.74 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL5252707 | 0.63 | GRIN2D (0.46) | KMT2AMEN1SMN1; SMN2HSD17B10 | |
| SCHEMBL3008905 | 0.63 | EPHX2 (0.36) | EPHX2KMT2AMEN1PKMCCKBR | |
| SCHEMBL3008912 | 0.63 | EPHX2 (0.36) | EPHX2KMT2AMEN1PKMCCKBR | |
| SCHEMBL3002776 | 0.62 | MEN1 (0.35) | EPHX2KMT2AMEN1PKMCCKBR | |
| SCHEMBL3002773 | 0.62 | MEN1 (0.35) | EPHX2KMT2AMEN1PKMCCKBR | |
| SCHEMBL21244858 | 0.61 | POLB (0.46) | EPHX2KMT2AMEN1PKMSMN1; SMN2 | |
| SCHEMBL3004569 | 0.60 | MEN1 (0.36) | EPHX2KMT2AMEN1PKMHSD11B1 | |
| SCHEMBL7528268 | 0.58 | MEN1 (0.42) | EPHX2KMT2AMEN1PKMHSD11B1 | |
| Hydrochloric Acid SCHEMBL31570944 | 0.57 | MEN1 (0.41) | EPHX2KMT2AMEN1PKMHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835426-B2 | Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2125750-B1 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20100197675-A1 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-08-05 | — | — | US | disclosed |
| EP-2125750-A2 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008106128-A2 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197675-A1 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD11B2 | EPHX2 1527/4885KMT2A 3759/4885MEN1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.